Objective: The start-up phase of a clinical trial (CT) plays a vital role in execution of novel drug development. Hence, this study aims to identify the factors responsible for delaying the CT start-up phase. Further, it focuses on streamlining and reducing the cycle time of the start-up phase of newly sponsored CTs. Methodology: Thirteen sponsored CTs conducted (between 2016 and 2017) in clinical research 3 Conclusion: Varied factors are responsible for delay of the start-up phase of CTs and understanding the impact of each factor allows for optimization and faster execution of the start-up phase of CTs.
Fishbone analysis was used to understand the potential causes of process variation. Mean time was calculated for each metrics prior to and post implementation of the intervention protocol to analyze and compare percentage reduction in the mean cycle time of CTs.
Results: Of the various potential factors of delay identified through Fishbone analysis, the two major ones were lack of well-defined timeline for approval and review of the study protocol; and inconsistent IRB meetings. Post introduction of the new intervention protocol, the entire CT lifecycle was reduced by 45.6% (24.8 weeks' vs 13 weeks, before and after intervention, respectively).
Introduction
Clinical trials (CTs) are essential for testing new drugs, devices and development of new treatment [1] . CTs are widely acknowledged for their role in determining the effectiveness of various therapeutic strategies and diagnostic tests [2] . However, several challenges mask the success of a CT; such as diverse stakeholders (sponsors, investigators, patients, payers, physicians and regulators), infrastructure, logistics, time or other support systems (informatics and manpower) [3] . It has been noted that the start-up phase of a trial sets the tone of the trial and plays an important role in determining the study success. However, starting a clinical trial (CT) is a complicated and time-consuming process. It requires significant understanding of various ethical committees, regulatory bodies and insights into a number of key steps like writing a protocol, applying for funding, and obtaining approvals from all involved stakeholders [4] .
Additionally, difficulty in patient recruitment is considered as one of the major reasons of delay in the overall drug development process [2] . The initiation of a new CT usually starts with a research hypothesis, followed by protocol writing, budget and contract negotiation, regulatory essential documents collection, development of a patient recruitment strategy and approvals from the research and development (R&D) department, ethics and other relevant regulatory bodies [4, 5] . On a whole, the start-up phase represents a significant and logistical undertaking [6] . However, duration of the start-up phase generally varies among sites and depends on trial complexity [6, 7] . FOCUS-PDCA is an effective method to systematically solve a simple/complex clinical process problem. It aids in problem solving, change implementation, and continuous improvement in the process [10] . We examined the current process for the start-up phase of new sponsored clinical studies, and used a fishbone analysis to clarify the current knowledge of the process and to understand the causes of process variation.
We used the data available at our site from previous study start-ups to characterize the role of 
Results
The original start-up phase resulted in a serious delay exceeding 24.8 weeks pending IRB submission. This resulted due to deferral in the PCLM and IDS pharmacy approvals (Figure 1 ). Therefore, in the original start-up phase, approvals from IDS pharmacy and PCLM must be in 7 place before the study package is submitted to IRB. This would help the trial to be on track and prevent any obvious scope of delay for subject recruitment.
Our fish-bone analysis identified numerous reasons for the delay in the current start-up phase and are presented in Figure 2 . Two major factors identified were: (i) lack of well-defined timeline for IDS pharmacy, PCLM review, and approval of the study protocol; and (ii) inconsistent convening of the IRB meetings.
Before implementation of the new interventional steps, the mean cycle time of the start-up phase of the new sponsored clinical studies used to be 24.8 weeks. While, after the intervention, the whole process took a maximum of 13 weeks (Table 1) . Therefore, with the new interventional protocol, 45.6% shortening of the entire CT lifecycle was noticed ( Figure 3 ).
Discussion
Findings of our study demonstrated an overall reduction in the mean cycle time of the start-up phase of newly sponsored CTs that gets un-necessarily prolonged due to axillary services required in beginning of the trial. Mainly, inconsistent convening of the IRB meetings, and the extensive period required to obtain approval from IDS pharmacy and PCLM on the study protocol plays as culprit in delaying the start-up phase of a CT. Similar points were also noted by Giffin RB et al.
(2010) [3] .
While recent studies have reported improved trends in the overall conduct of CTs, sponsors continue to experience significant challenges in meeting overall CT timeline demands [11] [12] [13] [14] .
Sites must perform several specific activities related to documentation, submissions, agreement approval, and patient visit schedules [4] [5] [6] . Historically, the study start-up phase has been viewed as a labor intensive, costly, and time-consuming component of the CT process. Several inefficiencies and limitations continue to threaten the prompt study start-up. Also, impeding efforts in this area is a lack of industry standards regarding the terms or milestones to measure [6] . 8 Krafcik et al reported a faster execution of the start-up phase and better subject enrollment with an earlier IRB approval. [6] . Further The present study provides a better insight and understanding of the varied steps involved in the start-up phase of a CT. These can efficiently help in reducing the time-lag period in initial CT stages and its associated costs. However, large multi-center studies are required to further support the present findings.
The emergence of newer approaches and strategic intervention protocols to streamline burdensome and time-consuming pre-initiation procedures offer promise, however, with the still uneven adoption of automated and integrated data systems, challenges in predicting start-up timelines and identifying potential holdups will continue. Elimination of the outsider forces to avoid further delay in the pre-initiation stage is a pre-requisite for timely conductance of CT.
Conclusion
Although notable improvement has been made in the way start-up phase activities are conducted, there remains much work to be done if true efficiencies are to be achieved in CT performance to increase predictability in site start-up. 
